サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1324961

着床前遺伝子診断（PGD）の世界市場

Preimplantation Genetic Diagnosis (PGD)
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 173 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
着床前遺伝子診断（PGD）の世界市場
出版日: 2023年08月09日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 173 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

着床前遺伝子診断（PGD）の世界市場は2030年までに1億6,040万米ドルに達する

変化するポストCOVID-19のビジネス環境において、2022年に1億900万米ドルと推定される着床前遺伝子診断（PGD）の世界市場は、2030年までに1億6,040万米ドルの市場規模に達すると予測され、2022年から2030年にかけてCAGR 5%で成長すると予測されます。本レポートで分析したセグメントの1つである染色体異常は、CAGR 4.2％を記録し、分析期間終了までに3,360万米ドルに達すると予測されます。現在進行中のパンデミック後の回復を考慮し、異数性分野の成長は今後8年間のCAGRを4.6%に修正しました。

米国市場は2,930万米ドル、中国はCAGR 7.3％で成長すると予測

米国の着床前遺伝子診断（PGD）市場は、2022年には2,930万米ドルになると推定されます。世界第2位の経済大国である中国は、2022年から2030年までの分析期間においてCAGR 7.3%で推移し、2030年までに3,460万米ドルの市場規模に達すると予測されています。その他の注目すべき地理的市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ2.8%と4.4%の成長が予測されています。欧州では、ドイツがCAGR約2.9%で成長すると予測されています。

調査対象企業の例

  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings（LabCorp）
  • Natera, Inc.
  • PerkinElmer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP14183

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Preimplantation Genetic Diagnosis (PGD) Market to Reach $160.4 Million by 2030

In the changed post COVID-19 business landscape, the global market for Preimplantation Genetic Diagnosis (PGD) estimated at US$109 Million in the year 2022, is projected to reach a revised size of US$160.4 Million by 2030, growing at aCAGR of 5% over the period 2022-2030. Chromosomal Abnormalities, one of the segments analyzed in the report, is projected to record 4.2% CAGR and reach US$33.6 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Aneuploidy segment is readjusted to a revised 4.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $29.3 Million, While China is Forecast to Grow at 7.3% CAGR

The Preimplantation Genetic Diagnosis (PGD) market in the U.S. is estimated at US$29.3 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$34.6 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.8% and 4.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Select Competitors (Total 46 Featured) -

  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Natera, Inc.
  • PerkinElmer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Preimplantation Genetic Diagnosis (PGD) - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Chromosomal Abnormalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for Chromosomal Abnormalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Aneuploidy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for Aneuploidy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for X-linked Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 8: World 8-Year Perspective for X-linked Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Single Gene Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 10: World 8-Year Perspective for Single Gene Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for HLA Typing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 12: World 8-Year Perspective for HLA Typing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Gender selection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 14: World 8-Year Perspective for Gender selection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Other PGD Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 16: World 8-Year Perspective for Other PGD Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
    • TABLE 17: World Preimplantation Genetic Diagnosis (PGD) Market Analysis of Annual Sales in US$ for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 19: USA 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 21: Canada 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • JAPAN
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 23: Japan 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • CHINA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 24: China Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 25: China 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • EUROPE
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 27: Europe 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 28: Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 29: Europe 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • FRANCE
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 30: France Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 31: France 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • GERMANY
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Germany 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • ITALY
    • TABLE 34: Italy Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 35: Italy 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • UNITED KINGDOM
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 36: UK Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 37: UK 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • SPAIN
    • TABLE 38: Spain Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Spain 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • RUSSIA
    • TABLE 40: Russia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 41: Russia 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 42: Rest of Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 43: Rest of Europe 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2023 & 2030
    • TABLE 46: Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 47: Asia-Pacific 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • AUSTRALIA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 48: Australia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 49: Australia 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • INDIA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 50: India Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 51: India 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • SOUTH KOREA
    • TABLE 52: South Korea Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 53: South Korea 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 54: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 55: Rest of Asia-Pacific 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • LATIN AMERICA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 56: Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 57: Latin America 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2023 & 2030
    • TABLE 58: Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 59: Latin America 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • ARGENTINA
    • TABLE 60: Argentina Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 61: Argentina 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • BRAZIL
    • TABLE 62: Brazil Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Brazil 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • MEXICO
    • TABLE 64: Mexico Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 65: Mexico 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 66: Rest of Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 67: Rest of Latin America 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • MIDDLE EAST
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 68: Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR
    • TABLE 69: Middle East 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2023 & 2030
    • TABLE 70: Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 71: Middle East 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • IRAN
    • TABLE 72: Iran Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 73: Iran 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • ISRAEL
    • TABLE 74: Israel Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Israel 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • SAUDI ARABIA
    • TABLE 76: Saudi Arabia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 77: Saudi Arabia 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 78: UAE Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 79: UAE 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 80: Rest of Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Rest of Middle East 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030
  • AFRICA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 82: Africa Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR
    • TABLE 83: Africa 8-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2023 & 2030

IV. COMPETITION